Abstract 485P
Background
Afatinib is indicated for the treatment of EGFR mutation-positive (M+) non-small cell lung cancer (NSCLC). LUX-Lung trials have demonstrated that afatinib significantly improved progression-free survival (PFS) compared with chemotherapy. We report results from a retrospective study of first-line afatinib in Korean patients with EGFR M+ NSCLC in real-world setting of two hospitals in South Korea.
Methods
Clinical data of Korean patients with stage IV EGFR M+ NSCLC who received first-line afatinib treatment in Pusan National University Yangsan Hospital and Pusan National University Hospital between February 2015 to December 2016 were obtained. Objective response rate (ORR), disease control rate (DCR), PFS, and tolerability were assessed. The treatment response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). PFS was estimated by Kaplan-Meier method and the differences in survival were assessed by log-rank test.
Results
A total of 99 eligible patients were enrolled for analysis. Mean age was 68 years (range: 35-83 years) and 56.6% were female. A total of 96.0% patients were histologically diagnosed with adenocarcinoma with 52.0% brain metastases (BM). ORR was 63.4% and DCR was 93.5%. Intracranial response was 69.6% in patients treated with afatinib plus local therapy and 55.0% with afatinib therapy alone. Median PFS reached 15.1 (95% CI: 12.6-17.4) months in overall, 12.6 (9.9-14.5) months in exon 19 deletion, 16.9 (12.5-21.1) months in exon 21 L858R mutation, 13.1 (1.9 to 22.3) months in rare mutations, 18.6 (14.9-24.2) months in BM absent, and 12.2 (10.9-15.2) months BM present. There is no significantly difference between PFS either by mutation types or by BM status. The most common Grade ≥3 side effects were skin rash/acne (15.2%), and diarrhea (10.1%).
Conclusions
This study indicates that the clinical outcomes achieved with first-line afatinib in Korean patients in real-world setting appear to be better than observed from the LUX-Lung studies. Afatinib can also provide a good intracranial response in patients with brain metastases regardless of whether or not they also receive local treatment.
Clinical trial identification
Editorial acknowledgement
Dr. Luke for the review and helpful comments for this study.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
248P - Retrospective review of metastatic carcinoma of cervix from a tertiary cancer institute of south India
Presenter: Arkoprovo Halder
Session: Poster display session
Resources:
Abstract
249P - Accuracy of endometrial biopsy by Pipelle: A systematic review and meta-analysis
Presenter: Jinhai Gou
Session: Poster display session
Resources:
Abstract
250P - Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities
Presenter: Gonçalo Nogueira da Costa
Session: Poster display session
Resources:
Abstract
251P - A prognostic index model for predicting long-term recurrence of uterine leiomyoma after initial myomectomy in women aged 18-44 years
Presenter: Xiu Ming
Session: Poster display session
Resources:
Abstract
252P - Uterine sarcomas in Qatar: Clinico-pathological characteristics and treatment outcome
Presenter: Ashraf Fadlelseid
Session: Poster display session
Resources:
Abstract
253P - Anti-PD-1-induced reinvigoration of tumour-infiltrating CD8+ T cells in epithelial ovarian cancer patients is correlated with T cell factor-1
Presenter: Junsik Park
Session: Poster display session
Resources:
Abstract
254P - Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)
Presenter: Diar Aziz
Session: Poster display session
Resources:
Abstract
255P - MEX3A is a prognostic biomarker and correlates with RNA splicing and cell proliferation in endometrial cancer by analysis of RNA-seq data
Presenter: Huining Jing
Session: Poster display session
Resources:
Abstract
256P - Lnc-AL445665.1-4 may be involved in the development of multiple uterine leiomyoma through interacting with miR-146b-5p
Presenter: E Yang
Session: Poster display session
Resources:
Abstract
257P - Treatment results of low risk gestational trophoblastic neoplasia (GTN) from a tertiary hospital, Chennai, India
Presenter: Rakesh M. P
Session: Poster display session
Resources:
Abstract